NEW BRUNSWICK, NJ—The Carlyle Group, a global private equity investment firm based in Washington, D.C. will be offering $4.16 billion to Johnson and Johnson for its blood testing and diagnostics unit.
The offer was announced in a press statement made by the NJ-based pharmaceutical giant on January 16.